Group 1 - BlackRock invested over $1.2 billion in ETH, significantly outpacing its $267 million investment in BTC, indicating a shift in Wall Street's capital direction from Bitcoin as "digital gold" to Ethereum as "digital oil" [1] - The rapid growth of BlackRock's Ethereum ETF (ETHA) from $5 billion to over $10 billion in just 10 days reflects changing investor sentiment towards Ethereum [1] Group 2 - Huajian Medical announced its transformation into the first enhanced Ethereum treasury company in Hong Kong, marking a strategic advancement in the market [2] - The company initiated a global enhanced Ethereum treasury strategy with a multi-layered "downside protection" mechanism and active "yield enhancement" strategies [3] Group 3 - Huajian Medical partnered with HashKey Group to establish a compliant trading channel for large-scale ETH transactions and to explore the integration of crypto assets with real-world assets (RWA) [6] - The company approved the purchase of 5,190 ETH at an average price of HKD 28,798.21, totaling HKD 149 million, as a significant step in its treasury strategy [7] Group 4 - Wall Street's consensus indicates that Ethereum is becoming a necessary asset for institutional investment, supported by five core value pillars including its deflationary nature and yield generation capabilities [8][9] - Ethereum's role as a foundational settlement asset in the DeFi ecosystem positions it as a preferred choice for RWA tokenization and stablecoin issuance [9] Group 5 - Huajian Medical's Ethereum treasury strategy is closely linked to its core business of medical RWA tokenization, aiming to create a unique ecosystem for innovative drug assets [10] - The company's ivd.xyz exchange is designed to facilitate the issuance and trading of medical RWA, integrating Ethereum as a core asset for governance and liquidity [10] Group 6 - The treasury strategy includes an "insurance mechanism" to mitigate volatility risks and a systematic investment approach to smooth costs [13][14] - Huajian Medical aims to address the challenges in innovative drug development financing through its tokenization strategy, enhancing investment efficiency [15] Group 7 - The market is recognizing the potential for Huajian Medical's treasury model to achieve significant valuation, drawing parallels to MicroStrategy's success with Bitcoin [17] - The company's stock price surged by 118% in July and 38.43% on August 6, indicating strong market interest and potential for value discovery [19] Group 8 - Huajian Medical's strategic vision includes applying for stablecoin licenses in both Hong Kong and the U.S., aiming to connect innovative drug assets with global capital through the Ethereum ecosystem [24] - The company's ambition is to leverage Ethereum's properties to create a new benchmark in the Hong Kong market, facilitating the global circulation of Chinese biomedical assets [24]

Core Viewpoint - The company has officially launched a strategic upgrade to create a "Global Enhanced Ethereum (ETH) Treasury" with a focus on medical innovation and asset tokenization [1][2]. Group 1: Strategic Overview - The company aims to integrate Ethereum (ETH) as a core reserve asset to enhance the efficiency of medical innovation drug development and asset allocation [3][7]. - The new "ivd.xyz" exchange will focus on high-tech assets in global medical innovation, facilitating the tokenization of real-world assets (RWA) [1][2]. Group 2: Mechanisms and Protection Strategies - The board has authorized the management to establish a "verifiable, executable, and quantifiable" seven-layer protection mechanism to safeguard shareholders and RWA holders [5]. - Additional strategies include a "three-layer enhancement engine" to transform ETH assets from passive holding to active income generation and reinvestment [5][6]. Group 3: Market Context and Trends - The strategic move aligns with global trends in cryptocurrency asset allocation, particularly among institutional investors, and responds to regulatory frameworks in regions like Hong Kong and the U.S. [4][6]. - The company has drawn insights from leading practices in the cryptocurrency asset reserve field, referencing successful models from various global firms [6][7].

本 公 司 董 事 會（「董事會」）欣 然 宣 佈，為 推 進 本 集 團「全 球 增 強 版 以 太 坊（ETH） 金 庫」戰 略 的 快 速 落 地，經 董 事 會 決 議 批 准，本 公 司 將 可 最 多 動 用8.8億港元於 公 開 市 場 購 買 以 太 坊（ETH）作 為 儲 備 資 產。本 公 司 將 通 過 自 有 資 金 及 透 過 募 集 資 金 活 動 籌 集 的 資 金 來 加 大 購 買 額 度，將 依 上 市 規 則 適 時 作 出 進 一 步 公 告， 包 括 但 不 限 於 召 開 股 東 大 會 通 過 加 大 購 買 額 度 等。本 公 司 已 通 過 香 港 持 牌 虛 擬資產交易所HashKey Exchange完 成 首 批 以 太 坊（ETH）的 合 規 購 買，並 計 劃 通 過 定 投 式 加 倉 策 略 持 續 增 持，目 標 成 為 港 股 市 場 乃 至 全 球 以 太 坊（ETH）儲 備 規 模 領 先 的 上 市 公 司。 截 至 本 公 告 日，本 公 司 首 批 合 共 買 入5,190枚 以 太 坊（ETH），每 枚 平 均 價 格 為 28, ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何 責 任。 IVD Medical Holding Limited 華檢醫療控股有限公司 （於開曼群島註冊成立之有限公司） （股份代號：1931） 自願性公告 打 造「全 球 增 強 版 以 太 坊（ETH）金 庫」、升 維 公 司 全 球 戰 略、為 生 態 參 與 者創造價值 本 公 告 由 華 檢 醫 療 控 股 有 限 公 司（「本公司」或「華檢醫療」，連 同 其 附 屬 公 司 統 稱「本集團」）董 事 會（「董事會」）自 願 作 出，旨 在 向 股 東、潛 在 投 資 者 及 市 場 各 方 全 面 闡 述 本 集 團 最 新 戰 略 升 級 暨 升 維 舉 措－經 董 事 會 決 議 通 過，本 集 團 正 式 啟 動「具 備 下 行 保 護 機 制 的 全 球 增 強 版 以 太 坊（ETH）金 庫」戰 略（「以 太 坊（ETH） 金庫戰略」） ...

Core Viewpoint - Huajian Medical has transformed from an IVD distributor to a "medical innovation drug chain investment bank" within 18 days, driven by a series of strategic actions and market enthusiasm, resulting in a significant increase in market capitalization from 3.6 billion to nearly 8 billion HKD [1][7]. Group 1: Strategic Actions - On July 14, Huajian Medical announced its plan for a dual primary listing on NASDAQ to expand its international shareholder base [4]. - Three days later, the company introduced the world's first medical innovation drug RWA exchange, IVDNewCo Exchange, along with a supporting stablecoin, IVDDollar (IVDD) [4]. - The establishment of a wholly-owned subsidiary, IVD GROUP INC., in New York was completed on July 20, with applications for stablecoin licenses submitted to the SEC and CFTC [4]. - From July 23 to 28, the company executed three high-priced buybacks, spending over 6.13 million HKD to repurchase 1.721 million shares, with average transaction prices rising from 3.16 HKD to 3.67 HKD [4]. - On July 29, the subsidiary Weida secured a multi-million HKD revolving loan led by East Asia Bank, showcasing financial institutions' endorsement of the company's development [4]. - A brand strategy upgrade was announced on July 30, with a new logo and a redefined brand essence of "Innovation-Verification-Development" [4]. - The same day, a partnership was formed with BGI's CoWin to establish an innovative drug intellectual property tokenization fund, facilitating the last mile of medical asset blockchain integration [4]. Group 2: Market Dynamics - The innovative drug industry is experiencing a value reassessment, with 48 out of 93 new drugs approved by the drug regulatory agency in 2024 being innovative drugs, and the scale of outbound licensing transactions soaring to 51.9 billion USD [8]. - As of July 29, the China Securities Hong Kong Stock Connect Innovative Drug Index has risen over 124% from its low point at the beginning of the year, with 16 innovative drug funds doubling their returns [8]. - The global regulatory landscape for stablecoins is evolving, with the U.S. "Genius Act" and Hong Kong's stablecoin regulations coming into effect, establishing a compliance network across Europe, the U.S., and Asia [8]. Group 3: Valuation Revolution - Following the announcement of the dual listing on July 14, Huajian Medical's stock price began a rapid ascent, with a cumulative increase of 75.1% from July 14 to 21 [9]. - On July 31, the stock price peaked at 4.99 HKD, marking a 15.78% increase for the day, and pushing the market capitalization to 8 billion HKD [9]. - The company's valuation is shifting from a traditional IVD distributor's sales multiple to an ecological premium associated with the medical RWA exchange [9]. Group 4: Future Outlook - Huajian Medical aims to become a leader in the medical RWA sector, akin to NASDAQ for medical asset tokenization, Visa for stablecoin payment scenarios, and Apple for integrating technology, assets, and capital into a closed loop [12]. - The global RWA market is projected to reach 16.1 trillion USD by 2030, with stablecoin transaction volumes expected to surpass Visa in 2024 [10]. - The company's strategy involves creating a closed-loop ecosystem that captures innovative drug pipelines, facilitates RWA tokenization, and enables payment settlements through IVDD stablecoin [10].

Core Viewpoint - The rapid transformation of Huajian Medical into a "new species" in the capital market is driven by its strategic actions, including a dual primary listing in the U.S. and the launch of innovative financial products, resulting in a significant increase in market capitalization from 3.6 billion to nearly 8 billion HKD within a month [1][4][9]. Group 1: Strategic Actions - On July 14, Huajian Medical announced its plan for a dual primary listing on NASDAQ to expand its international shareholder base [4]. - Three days later, the company introduced the world's first medical innovation drug RWA exchange, IVDNewCo Exchange, along with a stablecoin, IVDDollar [5]. - The establishment of a wholly-owned subsidiary, IVD GROUP INC., in New York was announced on July 20, alongside applications for stablecoin licenses to the SEC and CFTC [5]. - From July 23 to 28, the company executed three high-priced share buybacks, spending over 6.13 million HKD to repurchase 1.721 million shares, with average transaction prices rising from 3.16 HKD to 3.67 HKD [5]. - On July 29, the subsidiary Weishida secured a multi-hundred million HKD revolving loan led by East Asia Bank, indicating strong backing from financial institutions [5]. - A brand strategy upgrade was announced on July 30, featuring a new logo symbolizing "innovation-validation-development" [5]. - The same day, a partnership with BGI Group was established to create an innovative drug intellectual property tokenization fund, enhancing the integration of medical assets on the blockchain [5]. Group 2: Market Dynamics - The innovative drug industry is experiencing a value reassessment, with 48 out of 93 new drugs approved by the drug regulatory agency in 2024 being innovative drugs, and the scale of outbound licensing transactions soaring to 51.9 billion USD [10]. - As of July 29, the China Securities Hong Kong Stock Connect Innovative Drug Index has risen over 124% from its low point at the beginning of the year, with 16 innovative drug funds doubling their returns [10]. - The global regulatory landscape for stablecoins is evolving, with the U.S. "Genius Act" and Hong Kong's stablecoin regulations coming into effect, establishing a compliance network across Europe, the U.S., and Asia [10]. Group 3: Valuation Revolution - Following the dual listing announcement on July 14, Huajian Medical's stock price surged, with a cumulative increase of 75.1% from July 14 to 21, and a peak price of 4.99 HKD per share on July 31, pushing its market capitalization to 8 billion HKD [11]. - The company's valuation is shifting from traditional IVD distribution metrics to a premium associated with its new role as a medical RWA exchange [11]. Group 4: Future Outlook - The global RWA market is projected to reach 16.1 trillion USD by 2030, with stablecoin transaction volumes expected to surpass Visa's by 2024 [12]. - Huajian Medical aims to create a closed-loop ecosystem, capturing innovative drug pipelines, tokenizing RWA, and facilitating payments through its stablecoin [12]. - The company aspires to become a leader in the medical RWA sector, akin to NASDAQ for asset tokenization, Visa for stablecoin payments, and Apple for integrating technology and capital [14].

Core Viewpoint - The surge in Huajian Medical's stock price is driven by its announcement to apply for stablecoin issuance licenses in Hong Kong and the U.S., positioning itself as a pioneer in the medical technology sector for stablecoin issuance [2][3][4]. Group 1: Stock Performance - On July 21, Huajian Medical's stock opened significantly higher, peaking at a 58% increase, and closed up 32.88% at HKD 3.92 per share, with a market capitalization of HKD 6.356 billion [2]. - The company experienced a cumulative stock increase of 60% over two days, with trading volume exceeding HKD 50 million [2]. Group 2: Business Developments - On July 17, Huajian Medical announced the initiation of its stablecoin issuance license application process with relevant regulatory bodies in Hong Kong and the U.S. [2][3]. - The company’s U.S. subsidiary, IVDGROUPINC., has completed its registration and is now officially starting the stablecoin license application process [3]. Group 3: Market Reactions and Analysis - The market has shown mixed reactions to Huajian Medical's cross-industry initiatives, with some skepticism regarding its motives and the potential for "storytelling" [3]. - Analysts suggest that the company's approach addresses long-standing issues in the innovative drug sector, such as low liquidity and long financing cycles, by creating a Real World Asset (RWA) exchange focused on medical innovation [3][4]. Group 4: Regulatory Environment - Recent legislative developments in Hong Kong and the U.S. provide a favorable regulatory framework for stablecoin operations, enhancing Huajian Medical's strategic positioning [4]. - The Hong Kong Legislative Council's approval of the Stablecoin Bill marks a significant regulatory milestone, establishing a comprehensive framework for stablecoins and attracting Web3 projects to the region [4]. Group 5: Future Outlook - Market sentiment indicates confidence in the "innovative drug + stablecoin" integration, with expectations that Huajian Medical's RWA ecosystem could reshape valuation logic in the medical innovation sector [5]. - The potential for the company's stock to continue rising remains a point of interest for investors as it navigates the stablecoin landscape [5].